PDF herunterladen
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2017; 75(01): 57-65
DOI: 10.1590/0004-282X20160185
Guidelines

Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology

Orientações para tratamento da esclerose múltipla no Brasil: Consenso do Departamento Científico de Neuroimunologia da Academia Brasileira de Neurologia
Elizabeth Regina Comini-Frota
1   Universidade José do Rosário Vellano, UNIFENAS, Belo Horizonte MG, Brasil
4   Academia Brasileira de Neurologia, Departamento Científico de Neuroimunologia (DCNI), São Paulo SP, Brasil
,
Cláudia C. F. Vasconcelos
2   Universidade Federal do Estado do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil
4   Academia Brasileira de Neurologia, Departamento Científico de Neuroimunologia (DCNI), São Paulo SP, Brasil
,
Maria Fernanda Mendes
3   Santa Casa de São Paulo, Departamento de Neurologia, São Paulo SP, Brasil
4   Academia Brasileira de Neurologia, Departamento Científico de Neuroimunologia (DCNI), São Paulo SP, Brasil
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

ABSTRACT

Multiple sclerosis has become an ever-increasing challenge to neurologists. With the release of the latest medications on the market, Brazilian neurologists feel divided between following their patients’ evolution in accordance with the strict rules established by the Brazilian Ministry of Health regarding drug distribution, or following disease progression and worsening in accordance with the evidence in the literature. Therefore, a systematic review of the main published treatment guidelines was conducted and an escalating therapy proposed for guiding multiple sclerosis patient treatment in Brazil.

RESUMO

A esclerose múltipla vem se tornando um desafio crescente para os neurologistas. Com o lançamento de novos medicamentos no mercado, os neurologistas brasileiros se encontram divididos entre, apesar da evolução dos seus pacientes, seguir as regras restritas estabelecidas pelo Ministério da Saúde para distribuição de medicamentos, ou ao contrário, considerar a progressão e piora da doença, em concordância com as evidências da literatura. Devido a este impasse foi realizada uma revisão sistemática sobre as principais orientações de tratamento publicadas e foi proposto um escalonamento terapêutico para orientar o tratamento dos pacientes com esclerose múltipla no Brasil.

Keywords:

multiple sclerosis - Consensus - treatment

Palavras-chave:

esclerose múltipla - Consenso - tratamento

Support:

DCNI Study Group collaborators: Kaimen-Maciel DR, Adoni T, Moreira M, Pimentel MAV, Grzesiuk AK, Brum DG, Gonçalves MVM, Finkelsztejn A, Damasceno A, Santos ALM, Teixeira AL. Neto APG, Silva DJ, Diniz D, Correa EC, Tosta ED, Figueira FF, Cabeça HLA, Becker J, D’Almeida JAC, Ferreira MLB, Parolin MKF, Papaiz-Alvarenga R, Melo RBS, Morales RR, Alves-Leon SV, Machado SCN, Ribeiro TCGJ, Winckler TCD, Junqueira TM.




Publikationsverlauf

Eingereicht: 10. September 2016

Angenommen: 22. September 2016

Artikel online veröffentlicht:
06. September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases. 2015;3(7):545-55. doi:10.12998/wjcc.v3.i7.545
  • 2 Ministério da Saúde (BR). Portaria N° 391, de 5 de maio de 2015. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Esclerose Múltipla. Diário Oficial União. 6 maio 2015;Seção1:40.
  • 3 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: clinical results of a multicenter, randomized, double-blind, placebo- controlled trial. Neurology 1993;43(4):655-61. doi:10.1212/WNL.43.4.655
  • 4 Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):662-7. doi:10.1212/WNL.43.4.662
  • 5 Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-94. doi:10.1002/ana.410390304
  • 6 Randomised double-blind placebo-controlled study of interferon beta- 1a in relapsing/remitting multiple sclerosis. Lancet 1998;352(9139):1498-504. doi:10.1016/S0140-6736(98)03334-0
  • 7 Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45(7):1268-76. doi:10.1212/WNL.45.7.1268
  • 8 Hartung H P, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018-25. doi:10.1016/S0140-6736(02)12023-X
  • 9 Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910. doi:10.1056/NEJMoa044397
  • 10 Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401. doi:10.1056/NEJMoa0909494
  • 11 Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-107. doi:10.1056/NEJMoa1114287
  • 12 Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-28. doi:10.1016/S0140-6736(12)61769-3
  • 13 O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-303. doi:10.1056/NEJMoa1014656
  • 14 Sormani MP, Rio J, Tintorè M, Signori A, Li D, Cornelisse P et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013;19(5):605-12. doi:10.1177/1352458512460605
  • 15 Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R et al. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. J Clin Neurosci. 2014;;21(11):1847-56. doi:10.1016/j.jocn.2014.01.018
  • 16 Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J et al. GRADE guidelines 3: rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-6. doi:10.1016/j.jclinepi.2010.07.015
  • 17 Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al. GRADE guidelines: 1. Introdction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94. doi:10.1016/j.jclinepi.2010.04.026
  • 18 Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G et al. GRADE guidelines :2. Framing the question and deciding an important outcomes. J Clin Epidemiol. 2011;64(4):395-400. doi:10.1016/j.jclinepi.2010.09.012
  • 19 Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BM et al. Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord. 2014;3(2):147-55. doi:10.1016/j.msard.2013.07.001
  • 20 Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M et al. Treatment optimization in MS: canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013;40(3):307-23. doi:10.1017/S0317167100014244
  • 21 Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L‥. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev. 2008;(2):CD005278. doi:10.1002/14651858.CD005278.pub3
  • 22 Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, Logan D et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disorder. 2012;5(4):205-20. doi:10.1177/1756285612450936
  • 23 La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F et al. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2014;7:CD009333. doi:10.1002/14651858.CD009333.pub2
  • 24 Wingerchuk DM, Carter JL Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225-40. doi:10.1016/j.mayocp.2013.11.002
  • 25 Dörr J, Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17(6):354. doi:10.1007/s11940-015-0354-5
  • 26 Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochran Datab Syst Rev. 2013;6:CD008933‥. doi:10.1002/14651858.CD008933.pub2
  • 27 Tullman MJ. A review of current and emerging therapeutic strategies in multiple sclerosis. Am J Manag Care. 2013;19(2 Suppl):S21-7.
  • 28 Meyniel C1, Spelman T, Jokubaitis VG, Trojano M, Izquierdo G, Grand'Maison F et al. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. PLoS One. 2012;7(6):e38661. doi:10.1371/journal.pone.0038661
  • 29 Nicholas R, Straube S, Schmidli H, Pfeiffer S, Friede T. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis. Mult Scler. 2012;18(9):1290-6. doi:10.1177/1352458511435715
  • 30 Damal K, Stoker E, Foley JF. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics. 2013;7:247-58. doi:10.2147/BTT.S53007
  • 31 Weber MS, Menge T, Lehmann-Horn K, Kronsbein HC, Zettl U, Sellner J et al. Current treatment strategies for multiple sclerosis: efficacy versus neurological adverse effects. Curr Pharm Des. 2012;18(2):209-19. doi:10.2174/138161212799040501
  • 32 Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol. 2014;122:343-69. doi:10.1016/B978-0-444-52001-2.00014-5